Cancer is an incurable dangerous disease, and the number of new infections keeps rising every day. Eric Lefkofsky has devised a new way to improve the treatment of breast cancer.EricLefkofsky is the founder of Tempus this is a start-up that deals with finding a cure for cancer.Tempus has partnered with the Medicine Department at the University of Chicago, and it aims at giving them vital genetic information that will assist them in formulating how to treat the cancer patients.This treatment plan is aimed at 1000 people who are suffering from breast cancer. The information will assist the medical personnel by helping them get patterns that will help them know how well they will react to the treatment. The cancer is one of the most occurring forms of the disease, but without vital genetic information treating, it is almost impossible.
Tempus was co-founded in 2015 by Eric Lefkofsky. The Cancer start-up employs the use of a machine to access genetic sequencing that will assist the doctors in getting the information that will assist in treatment.The Chicago-based company has also worked with The Mayo Clinic, Rush University Medical Center, Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, University of Michigan and Penn Medicine in the battle against cancer.
ABOUT ERIC LEFKOFSKY
This is a serial entrepreneur who is at the helm of various companies. Eric Lefkofsky is the CEO and co-founder of Tempus, the founder of Lightbank; he assisted in starting Uptake Technologies and the chairman and co-founder of Groupon.He is also the founder of the Lefkofsky Family Foundation.This is a charitable organization that he runs with his spouse which aims at developing the lives of various people. He is also a Trustee of Lurie Children’s Hospital in Chicago.
Tempus is a startup from Eric Lefkofsky, who is the founder of GroupOn. It is designed to fight breast cancer. With this, Eric Lefkofsky will be giving doctors at the University of Chicago a better way for treating the breast cancer patients.Tempus is based in Chicago. It has got into a partnership with the Medicine Thursday at the University of Chicago. Tempus will be providing molecular sequencing along with its analysis to the breast cancer specialists at UChicago. Such kind of data will be extremely in creating personalized treatment plans for the breast cancer patients.Find him on Facebook: Click here
Eric Lefkofsky has said that Tempus will be analyzing data of nearly 1,000 breast cancer patients. This will help in identifying patterns that can help doctors and researchers to predict how their patients will be responding to specific treatment.Eric Lefkofsky had established the Lefkofsky Family Foundation in 2006. This is a private charity foundation. It provides initiatives that are able to enhance lives of people in the communities.
Eric Lefkofsky is a Trustee of Lurie Children’s Hospital of Chicago, besides The Art Institute of Chicago, as well as The Museum of Science and Industry and of the World Business Chicago.Now he wants to help UChicago by providing it data that will lead to better treatment of the patient. The fact is that breast cancer is common cancer, but there is relatively very little accessible data available on the patients who have suffered this disease. This is why physicians are forced to treat patients without having any specific genetic information. In case this information was available, it would help in making better-informed decisions that were precise. This is why partnering with Tempus will be helpful. Tempus is making efforts to build the largest of molecular data set specifically in breast cancer which will be clinically annotated.
Cancer Research is one of the most talked about subjects in modern day times. The deadly disease is so widespread that just about everyone on earth has been affected in some form or way. Cancer medicines, treatments, procedures, and methods have changed throughout the years and there is one company that is currently leading the charge. Seattle Genetics is a biotechnology company led by Clay Siegall, that focuses on the development and commercialization of Antibody Based Therapies. This crucial fight against cancer is constantly evolving and with these specific therapies present, cancer is experiencing a devastating blow. Antibody Drug Conjugates are the stars of this style of therapy thanks to their affects on cancer and the human body. (ADCs) are highly affective because they deliver a devastating injection of cancer killing agents right into cancer cells.
This biotech company is led by Dr. Clay Siegall. Siegall has a huge resume of success within the industry, but it’s his strong passion to help others which sets him apart from his contemporaries. Dr. Siegall has a Ph.D in Genetics from George Washington University as well as a (BS) in Zoology from the University of Maryland. The question may be asked “is clay siegall over qualified?” When it comes to cancer I’d think it’s better to be over qualified than underqualified. Dr. Siegall is no novice to the field and has many years of experience in the business long before Seattle Genetics was founded.
The good doctor has worked with some of the most prestigious institutes in the world such as Bristol-Meyers Squibb and The National Institute of Health. With the huge success of Seattle Genetics (ADCETRIS) Technology, the company has multiple strategic licenses with organizations like AbbVie, Genentech, Pfizer, and GlaxoSmithKline. The future looks bright thanks to Clay Siegall and the leading cancer research center of Seattle Genetics.